Companies: 10,795·Total market cap: $144.5T
KALA BIO, Inc.

KALA BIO, Inc.

KALANASDAQHealthcare● Active
$2.34
+$0.28(+13.64%)
Market Cap$51335937
P/E Ratio
52W High$1030
52W Low$2.03

KALA BIO, Inc. (KALA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

kala · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 9 Wall Street analysts in the past 3 months

SellBuy

Buy

9 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
3
Sell
1
Strong Sell
0
Total: 9 · Buy rate: 55.6%

12-Month Price Target

High

$35.00

Consensus

$18.25

+652.5% upside

Low

$1.50

Median: $18.25 · Last Close: $2.43

The KALA BIO, Inc. (KALA) analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month KALA price target is $18.25, representing +652.5% upside from the current price of $2.43.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $18 (652.5%)

Consensus Target

$18.25

652.5% upside

High Target

$35

1343.1%

Low Target

$1.5

-38.2%

Current Price

$2.43

as of today

Based on analyst price targets, the KALA stock price prediction for the next 12 months ranges from $1.5 to $35. The consensus KALA price forecast of $18.25 implies 652.5% upside from the current price of $2.43.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$2.305.00%

1-day model range: $2.26–$2.35. Peak: $2.35 (-5.00%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

29%21%50%
4Buy
3Neutral
7Sell
RSI (14)42.7Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · KALA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$2.27BUY
MA 10$2.26BUY
MA 20$2.58SELL
MA 50$5.73SELL
MA 100$12.96SELL
MA 200$0.00NEUTRAL
Current $KALA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.28BUY
EMA 10$2.37BUY
EMA 20$3.00SELL
EMA 50$6.36SELL
EMA 100$13.91SELL
EMA 200$0.00NEUTRAL
Current $KALA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2025-09-29
Downgrade ↓
BuyNeutral
HC Wainwright & Co.2025-09-17
Maintains
BuyBuy
Oppenheimer2025-09-11
Maintains
OutperformOutperform
HC Wainwright & Co.2025-05-23
Maintains
BuyBuy
HC Wainwright & Co.2025-04-04
Maintains
BuyBuy
HC Wainwright & Co.2025-02-13
Maintains
BuyBuy
HC Wainwright & Co.2024-11-15
Maintains
BuyBuy
Oppenheimer2024-08-19
Maintains
OutperformOutperform
HC Wainwright & Co.2024-05-17
Maintains
BuyBuy
HC Wainwright & Co.2024-04-02
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on KALA BIO, Inc. (KALA) stock. Of the recent 48 rating actions, 0 were upgrades and 5 were downgrades. 9 analysts currently cover KALA.

Analyst Recommendation Trends

Buy ratings12↑ +1
Hold ratings01↑ +1
Sell ratings00

KALA analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$41M

↑ 58.3% YoY

Revenue Next Year

$25M

↓ 39.5% YoY

EPS This Year

$-222.50

EPS Next Year

$-26.50

↓ 88.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast KALA EPS of $-222.50 for the current fiscal year, based on estimates from 1 analysts. The KALA revenue forecast is $41M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The KALA stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KALA price target is $18.25 (+652.5% upside), with an analyst consensus of Buy.

The KALA short-term stock prediction for tomorrow is $2.30 (-5.00%).

KALA BIO, Inc. trades on NASDAQ under the ticker KALA. The KALA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

KALA forecast · 8 questions

According to 9 Wall Street analysts, the average 12-month KALA price target is $18.25, with a high forecast of $35.00 and a low of $1.50. The median price target is shown in the chart above when available. This implies +652.5% potential upside from the current price of $2.43.

KALA price targetWhat is KALA price targetKALA analyst price targetKALA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.